GLP-1 (7-37)

GLP-1(7-37) is the native 30-amino-acid active form of glucagon-like peptide 1, an endogenous incretin hormone secreted by intestinal L-cells in response to nutrient ingestion, that acts at GLP-1 receptors throughout the body to stimulate glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, reduce appetite, and protect beta-cell mass; it is the endogenous ligand underlying the pharmacology of the GLP-1 receptor agonist drug class. The GLP-1 receptor is expressed on pancreatic beta cells, hypothalamic appetite-regulating neurons, gastric enteric neurons, and cardiovascular tissue; GLP-1(7-37) activates cAMP/PKA signaling in beta cells to potentiate insulin release strictly during hyperglycemia, providing intrinsic hypoglycemia protection, and centrally reduces caloric intake through satiety signaling.

appetite suppression, insulin sensitivity, blood glucose regulation.

Research on GLP-1 (7-37) primarily documents effects related to appetite suppression and insulin sensitivity and blood glucose regulation. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

Reported contraindications and considerations for GLP-1 (7-37) include Personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), Known hypersensitivity to the drug or excipients. 7 additional considerations are noted in the safety profile above. This is educational information only — consult a qualified healthcare professional before use.

For GLP-1 (7-37), its FDA status is not evaluated by the FDA, and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

28 providers in the directory currently offer GLP-1 (7-37).

# Summary Research found that engineered compact fusion tags can significantly improve the recombinant expression and recovery of GLP-1(7-37) precursors in *E. coli* by optimizing the mass ratio between the target peptide and its cleavable protein tag. This study demonstrated that a specifically designed 4.0 kDa tag (LP8) achieved the highest yields by balancing inclusion body formation with minimal tag mass, offering a scalable manufacturing approach for GLP-1 analogs and other small peptide therapeutics.